Koji Tanabe, CEO of I Peace, Inc. honored by World Biz Magazine with “Top 100 Innovation CEO” Award
PALO ALTO, Calif., Sept. 22, 2021 /PRNewswire/ -- Koji Tanabe, Founder and CEO of I Peace, Inc. (https://www.ipeace.com ), has been selected by the judges of World Biz Magazine's annual awards to be a recipient of the "Top 100 Innovation CEO – 2021" (https://www.worldbizmagazine.net/ ). I Peace, Inc. is a Palo Alto-based biotech...
FII Institute Launches Global Infectious Diseases Index
FII Institute launched a unique global index that uses groundbreaking technology to track infectious diseases and transform how the world reacts to future crises. The Global Infectious Diseases Index was developed by FII Institute in partnership with Accenture and Metabiota. Metabiota's risk solution program was among the first to flag unusual...
FDA Approves LEXETTE (R) for Adolescent Plaque Psoriasis
RALEIGH, N.C., Sept. 21, 2021 /PRNewswire/ -- Mayne Pharma is pleased to announce that the U.S. Food and Drug Administration (FDA) has approved LEXETTE® (halobetasol propionate) foam, 0.05% for use in adolescents. LEXETTE, a super potent topical corticosteroid, is now approved for the treatment of plaque psoriasis in patients aged 12 years and older. The FDA approved LEXETTE in 2018...
Origin Agritech and China Agricultural University to Collaborate on Research of Molecular Design of Corn Using CRISPR
BEIJING, Sept. 21, 2021 /PRNewswire/ -- Origin Agritech Ltd. (NASDAQ: SEED) (the "Company" or "Origin"), an agriculture technology company, today announced that it has entered into collaboration agreement with China Agricultural University for the research of molecular design in corn. One of the key focuses of the collaboration is the use of CRISPR gene editing for creating innovative new corn crops. CRISPR...
Kyowa Hakko Acclaimed by Frost & Sullivan for its Non-GMO, Allergen-free, Immune Support Paraprobiotic Ingredient, IMMUSE™
The solution offers superior ease of formulation, potential application versatility, and more comprehensive immune support compared to probiotics and other immune health ingredients SANTA CLARA, Calif., Sept. 21, 2021 /PRNewswire/ -- Based on its recent analysis of the North American immune health ingredient market, Frost & Sullivan recognizes Kyowa Hakko USA, Inc. (Kyowa Hakko) with the 2021 North American...
Long-termism as Investment Philosophy: Healthcare Investor Sangel Capital Expects to See Big Rise in Investment Value
SHENZHEN, China, Sept. 201, 2021 /PRNewswire/ -- The portfolio value of Sangel Capital ("Sangel" or the "Company"), a leading biotech and healthcare venture capital company based in China, is poised for strong growth as multiple biotech and pharmaceutical companies backed by Sangel's venture funds have reported a succession of milestone achievements in...
Farrer Park Hospital Enhances Dementia services to Better Guide Management and Care Plan for People with Dementia
SINGAPORE, Sept. 21, 2021 /PRNewswire/ -- Farrer Park Hospital ("FPH" or "the Hospital") today announced that the Hospital has enhanced its dementia services to offer an enhanced artificial intelligence (AI)-supported MRI screening tool for dementia. Dementia is a neurodegenerative disease that occurs due to abnormal brain changes. According to HealthHub, about one in 10 (amongst the elderly aged 60...
Fullerton Health launches DigiHealth Kiosk to improve accessibility and affordability of healthcare for Migrant Workers
SINGAPORE, Sept. 21, 2021 /PRNewswire/ -- The COVID 19 Pandemic has shown the importance of primary care for all segments of society, including Migrants Workers. Miah Ratan, 33, Maintenance Supervisor Sashtha Construction, first user of the Fullerton DigiHealth Kiosk at North Coast Lodge. Fullerton Health...
Novavax to Participate in Fireside Chat at Devex @ UNGA 76
GAITHERSBURG, Md., Sept. 21, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing and commercializing next-generation vaccines for serious infectious diseases, today announced that John J. Trizzino, Executive Vice President, Chief Commercial Officer and Chief Business Officer, will be interviewed at Devex @ UNGA 76 on September 21 at...
RhoVac announces the completion of patient recruitment for the BRaVac clinical phase IIb study of RV001 in prostate cancer
STOCKHOLM, Sept. 21, 2021 /PRNewswire/ -- RhoVac AB ("RhoVac"), a Swedish cancer immunotherapy company, announces today on Sep 20th , 2021, that its clinical phase IIb study of lead drug candidate RV001 in prostate cancer, BRaVac, is deemed fully recruited and that no additional patients will be screened after this week. Top-line results of the study are estimated to be...
